TECH Bio-Techne Corporation
USHealthcareAs of 2026-07-09 11:57
Why TECH matters now
Bio-Techne Corporation (TECH) is a US stock in Healthcare. The latest InvestLog snapshot shows $71.17 with +0.29% on the session and $11.14B in market capitalization; recent performance reads 1-month +27.42% and YTD -1.48%.
The latest financial table shown here is Q3 2026, with revenue of $311.4M, net income of $51.1M, and EPS of $0.32. Investors can compare that operating picture with valuation signals such as P/E 103.84 and FCF yield 3.0%.
The latest indexable market news headline is "Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $56.00; recent insider activity includes Crouse Steven C. filing M-Exempt; recent congressional disclosure data includes April Delaney Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
103.84
PEG
—
P/B
4.33
P/S
7.49
EV/EBITDA
35.48
DCF Value
$22.78
FCF Yield
3.0%
Div Yield
0.6%
Margins & Returns
Gross Margin
65.0%
Operating Margin
12.7%
Net Margin
9.0%
ROE
5.5%
ROA
4.3%
ROIC
4.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $311.4M | $51.1M | $0.32 |
| Q2 2026 | $295.9M | $38.0M | $0.24 |
| Q1 2026 | $286.6M | $38.2M | $0.24 |
| Q4 2025 | $317.0M | $-17.7M | $-0.11 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$59.17
Target (Median)
$56.00
Target Range
$49.00 - $79.00
Trading Activity
Insider Trades
Congress Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.36
Bio-Techne Corporation, headquartered in Minneapolis, Minnesota, is a global enterprise specializing in the development, production, and distribution of specialized life science tools, instrumentation, and support solutions for both research and clinical diagnostic markets. The company is organized into two key business units: Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment manufactures a broad array of biological components, including cytokines, growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies, which are instrumental across life science research, diagnostic applications, and advancements in cell and gene therapy. This division further provides sophisticated proteomic analysis platforms, encompassing automated western blot and multiplexed ELISA workflows, coupled with relevant instrumentation and immunoassay kits designed for precise protein quantification in various biological fluids. The Diagnostics and Genomics segment is dedicated to developing and manufacturing diagnostic offerings, such as controls, calibrators, and specific diagnostic assays tailored for regulated markets. Its portfolio extends to innovative exosome-based molecular diagnostic tests, advanced in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and a variety of genetic and oncology kits for both research and clinical use. Additionally, this segment supplies products vital for genetic carrier screening, oncology diagnostics, molecular controls, and general research, alongside instrumentation and process controls for hematology, blood chemistry, gas analysis, and coagulation diagnostic applications. Its comprehensive product suite is offered under prominent brands including R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen. Founded in 1976 as Techne Corporation, the company adopted its current name, Bio-Techne Corporation, in November 2014.